MSACL 2019 US Abstract

Self-Classified Topic Area(s): Tox / TDM / Endocrine

Mass Spectrometry and Mass-Overdose in New Haven, Connecticut

Dustin R. Bunch (1), Thomas JS Durant (1), Daniel Nogee (1), Barry Logan (2) Sandy Bogucki (1), Asim Tarabar (1), Anthony Tomassini (1)
(1) Yale New Haven Hospital, New Haven, CT (2) Center for Forensic Science Research and Education, Willow Grove, PA

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Dustin Bunch (Presenter)
Yale-New Haven Hospital

Presenter Bio: Dr. Dustin R. Bunch received his BA in Biochemistry from Case Western Reserve University and his PhD in Clinical/Bioanalytical Chemistry from Cleveland State University. He is currently a Clinical Chemistry Fellow at Yale-New Haven Health System. He spent 10 years performing mass spectrometry assay research and development in Laboratory Medicine at the Cleveland Clinic. He has been a member of the American Association for Clinical Chemistry (AACC) since 2008 and served as a board member on the local section. He has served as the Northeast Ohio Section AACC liaison for the joint AACC, ASCLS, and CLMA Ohio Collaborative Laboratory Conference. Dustin won the NACB abstract award in 2013, the AACC Mass Spectrometry and Separation Science division abstract award in 2017, and the AACC Academy Distinguished Abstract in 2018.

Relevant Financial Disclosures (within past 24 months)

No relevant financial relationship(s) to disclose.

Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above.

Conflict mitigation NOT REQUIRED.

Abstract

In August 2018, New Haven, CT made national news when multiple non-responsive individuals were identified in the New Haven Green, a park in central New Haven. Clinical assays were unable to identify the drugs ingested so mass spectrometry needed to be applied to identify the drugs. A targeted synthetic cannabinoid screen (n=262) and broad drug and metabolite screen (n=700) LC-HRMS assays were used and identified 5F-ADB, 5F-MDMB-PICA, MMB-FUBINACA and/or their metabolites in patient urine (n=21). LC-HRMS was crucial to the investigation and identification of the compounds ingested during this mass-overdose event.